CleanCap ® Reagent AG is TriLink’s patented co-transcriptional capping reagent for in vitro transcription of 5’ capped mRNA resulting in a Cap 1 structure. CleanCap has shown to provide up to 98% capping efficiency.

In Depth Characterization of Immune Response Against the Spike Protein of Sars-CoV-2 in Response to Infection and mRna Vaccination. The hottest topics and cutting-edge research—straight to your inbox. Keep yourself up-to-date with the newest product releases, technical content, and upcoming events.

TriLink offers a robust portfolio of patented CleanCap ® cap analogs for use in the discovery or GMP manufacturing of vaccines, cell therapies, gene replacement therapies, and more, ensuring an optimal mRNA capping strategy to help maximize mRNA …

May 9, 2023 · Newest cap analog product improves mRNA potency with greater protein expression, offers time and cost savings, and streamlines manufacturing to drive critical therapeutic and vaccine development

TriLink has revolutionized mRNA capping strategies with its one-pot CleanCap capping solutions generating the optimal Cap1 structure with more than 95% efficiency. Shortens therapeutic mRNA manufacturing process time per batch by nearly a week compared to enzymatic capping.

Used in global commercial manufacturing programs, including a leading COVID-19 vaccine, CleanCap technology has proven to be the optimal mRNA vaccine capping method. See how we ramped up...

Feb 5, 2024 · TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology.

Feb 4, 2025 · Enabling the future development of critical therapeutics, Aldevron customers now have access to TriLink’s CleanCap mRNA capping technology for non-commercial use.

With a robust portfolio of RNA and associated small molecules, including non-coding RNAs and CleanCap capping solutions, TriLink provides tailored synthesis at milligram to multigram scales, with lengths ranging from a few hundred nucleotides to greater than 10 kilobases.

CleanCap capping solution reduces process development time by an estimated 50% compared to ARCA and enzymatic capping. mRNA manufacturing utilizing CleanCap technology saw an estimated 20-40% lower total costs than other methods.